Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00553059 · ClinicalTrials.gov registry record · Phase 3
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT00553059: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00553059 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00553059, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving chemotherapy. The safety of the drug combinations will also be studied.
Interventions
- OTHER placebo
- DRUG dexamethasone
- DRUG dronabinol
- DRUG palonosetron hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00553059
The ClinicalTrials.gov registry entry for NCT00553059 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00553059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00553059 about?
NCT00553059 is a clinical study titled "Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer". The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving chemotherapy. The safety of the drug combinations will also be studied.
What is the current status of trial NCT00553059?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2008-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00553059?
The interventions under investigation include: placebo (OTHER), dexamethasone (DRUG), dronabinol (DRUG), palonosetron hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00553059?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.